Reduction in salivary cortisol concentration correlates with resolution of psychosis in Cushing's syndrome

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 20, Issue 1, 2008, Pages 113-115

  Myhill, Paul C ^a   Sillars, Brett A ^a   Starkstein, Sergio ^b   Annus, Tibor ^b   Yeap, Bu B ^c  

^a FREMANTLE HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMILORIDE; CATECHOLAMINE; CORTICOTROPIN; HYDROCORTISONE; KETOCONAZOLE; LORAZEPAM; METYRAPONE; OLANZAPINE; POTASSIUM; RENIN; RISPERIDONE;

ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DIAGNOSTIC IMAGING; DRUG SALIVA LEVEL; HUMAN; HYPERTENSION; HYPOKALEMIA; LETTER; MALE; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT PLANNING;

EID: 39749085730     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2008.20.1.113     Document Type: Letter

References (5)

1. Findling JW, Raff H: Cushing's syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 2006; 91:3746-3753
2. Ferrari P: Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Pract Res Clin Endocrinol Metab 2003; 17:575-578
3. Kelly WF: Psychiatric aspects of Cushing's syndrome. QJM 1996; 89:543-551
4. Agid O, Kapur S, Arenovich T, et al: Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60:1228-1235
5. Brown ES, Chamberlain W, Dhanani N, et al: An open-label trial of olanzapine for corticosteroid-induced mood symptoms. J Affect Disord 2004; 83:277-281